Loading patent…
OwnerPaul R. Hinton, Bruce Alan Keyt +4inventors
InventorsPaul R. Hinton, Bruce Alan Keyt, Dean Ng, Kathy Miller, Deepal Pandya, Stephen F. Carroll
Estimating the term…
This disclosure provides multimeric binding molecules that bind to a human coronavirus, e.g., MERS-CoV, SARS-CoV or SARS-CoV-2. This disclosure also provides compositions comprising the multimeric binding molecules, polynucleotides that encode the multimeric binding molecules, and host cells that can produce the binding molecules. Further this disclosure provides methods of using the multimeric binding molecules, including methods for treating and preventing human coronavirus disease, e.g., coronavirus disease 2019 (COVID-19).
A multimeric binding molecule comprising two to six bivalent binding units or variants or fragments thereof, wherein each binding unit comprises two IgM or IgA heavy chain constant regions or multimerizing fragments or variants thereof, each associated with a binding domain, wherein three to twelve of the binding domains are identical and specifically bind to a human coronavirus, and wherein the binding molecule is more potent than a bivalent reference IgG antibody comprising two of the binding domains that specifically bind to the human coronavirus.
Dependencies are inferred from the claim text.